Benitec Story

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;'>BB</div>
BNTC -- USA Stock  

USD 2.79  0.09  3.12%

Benitec Biopharma Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to increase significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at 4.71 Million. The current year Earnings before Tax is expected to grow to about 5.1 M, whereas Average Assets are forecasted to decline to about 21.7 M. Benitec Biopharma is scheduled to announce its earnings tomorrow. The stock is undergoing a sell-off trend. As many risky investors are excited about healthcare space, it is only fair to go over Benitec Biopharma Limited based on its current volatility. We will cover the possibilities of making Benitec Biopharma into a steady grower in October. We currently estimate Benitec Biopharma as undervalued. The real value is approaching 7.75 per share.
Published over two months ago
View all stories for Benitec Biopharma | View All Stories
Are Benitec Biopharma (NASDAQ:BNTC) weak basic indicators contributing to the current slip?
We provide trade advice to complement the prevailing expert consensus on Benitec Biopharma. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. This firm dividends can provide a clue to the current value of the stock. Benitec Biopharma is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Benitec Biopharma income statement, its balance sheet, and the statement of cash flows. Potential Benitec Biopharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Benitec Biopharma investors may use each financial statement separately, they are all related. The changes in Benitec Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Benitec Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Benitec Biopharma fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Benitec Biopharma performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Benitec Biopharma shares is the value that is considered the true value of the share. If the intrinsic value Benitec is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Benitec Biopharma. Please read more on our fundamental analysis page.

Are Benitec Biopharma Earnings Expected to grow?

The future earnings power of Benitec Biopharma involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Benitec Biopharma factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Benitec Biopharma stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Benitec expected earnings.

How Benitec utilizes its cash?

To perform a cash flow analysis of Benitec Biopharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Benitec Biopharma is receiving and how much cash it distributes out in a given period. The Benitec Biopharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Benitec Biopharma Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (7.54 Million)

Benitec Biopharma Gross Profit

Benitec Biopharma Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Benitec Biopharma previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Benitec Biopharma Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Detailed Perspective On Benitec Biopharma

The big decline in price over the last few months for Benitec Biopharma could raise concerns from investors as the firm it trading at a share price of 5.80 on slow start in volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Benitec Biopharma Limited or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.32. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Benitec Biopharma partners.
 2017 2018 2019 2020 (projected)
Revenues USD280 K11.38 M13.09 M14.12 M
Revenues378 K16.16 M18.58 M20.05 M

Asset Utilization

One of the ways to look at asset utilization of Benitec is to check how much profit was generated for every dollar of assets it reports. Benitec Biopharma Limited shows a negative utilization of assets of -21.76 percent, losing $0.22 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Benitec Biopharma Limited shows how discouraging it operates for each dollar spent on its assets.

Current Assets
23.1 M
Current Assets23.1 Million97.19
Assets Non Current668,2282.81

Will price continue to rise in October 2020?

The variance is down to 21.2 as of today. Benitec Biopharma Limited exhibits very low volatility with skewness of 0.65 and kurtosis of 0.85. However, we advise investors to further study Benitec Biopharma Limited technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Benitec Biopharma

Whereas some other firms in the biotechnology industry are either recovering or due for a correction, Benitec may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither buy new shares of Benitec nor short your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Benitec Biopharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Benitec Biopharma Limited. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com